IL274162A - Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof - Google Patents

Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof

Info

Publication number
IL274162A
IL274162A IL274162A IL27416220A IL274162A IL 274162 A IL274162 A IL 274162A IL 274162 A IL274162 A IL 274162A IL 27416220 A IL27416220 A IL 27416220A IL 274162 A IL274162 A IL 274162A
Authority
IL
Israel
Prior art keywords
selenogalactoside
compounds
treatment
insulin resistance
systemic insulin
Prior art date
Application number
IL274162A
Other languages
Hebrew (he)
Original Assignee
Galectin Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences Llc filed Critical Galectin Sciences Llc
Publication of IL274162A publication Critical patent/IL274162A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IL274162A 2017-10-31 2020-04-23 Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof IL274162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579343P 2017-10-31 2017-10-31
PCT/US2018/032321 WO2019089080A1 (en) 2017-10-31 2018-05-11 Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof

Publications (1)

Publication Number Publication Date
IL274162A true IL274162A (en) 2020-06-30

Family

ID=66332241

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274162A IL274162A (en) 2017-10-31 2020-04-23 Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof

Country Status (8)

Country Link
EP (1) EP3707149A1 (en)
JP (1) JP2021501180A (en)
KR (1) KR20200081443A (en)
CN (1) CN111527097A (en)
AU (1) AU2018361991A1 (en)
CA (1) CA3080128A1 (en)
IL (1) IL274162A (en)
WO (1) WO2019089080A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45491A (en) * 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
CN116063520A (en) 2019-01-30 2023-05-05 真和制药有限公司 anti-GAL 3 antibodies and uses thereof
KR20220044785A (en) 2019-08-09 2022-04-11 이도르시아 파마슈티컬스 리미티드 (hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
WO2021028323A1 (en) * 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
BR112021026829A2 (en) 2019-08-15 2022-02-22 Idorsia Pharmaceuticals Ltd Compound, pharmaceutical composition, use of a compound, and method for the prophylaxis or treatment of organ fibrosis; liver diseases and disorders; cardiovascular diseases and disorders; cell proliferative diseases and cancers; inflammatory and autoimmune diseases and disorders; diseases and disorders of the gastrointestinal tract; pancreatic diseases and disorders; diseases and disorders associated with abnormal angiogenesis; diseases and disorders associated with the brain; neuropathic pain and peripheral neuropathy; eye diseases and disorders; acute kidney injury and chronic kidney disease; interstitial lung diseases and disorders; or transplant rejection
EP4021904B1 (en) 2019-08-29 2024-01-03 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
MX2022006713A (en) * 2019-12-06 2022-07-12 Truebinding Inc Antibodies that disrupt the interaction of gal3 and insulin receptor or integrins and methods of use thereof.
JP2023545046A (en) 2020-10-06 2023-10-26 イドーシア ファーマシューティカルズ リミテッド Spiro derivatives of alpha-D-galactopyranoside
TW202233609A (en) 2020-11-02 2022-09-01 瑞士商愛杜西亞製藥有限公司 2-hydroxycycloalkane-1-carbamoyl derivatives
CN112190590A (en) * 2020-11-06 2021-01-08 牡丹江医学院 Selenium nucleoside for treating atherosclerosis and pharmaceutical composition thereof
WO2022171594A1 (en) 2021-02-09 2022-08-18 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
US20240109930A1 (en) 2021-03-03 2024-04-04 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016120403A1 (en) * 2015-01-30 2016-08-04 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN105318222B (en) * 2015-11-13 2018-07-27 南通亚泰蜡业工艺品有限公司 Fountain electric candle
WO2017152048A1 (en) * 2016-03-04 2017-09-08 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof

Also Published As

Publication number Publication date
JP2021501180A (en) 2021-01-14
WO2019089080A9 (en) 2020-07-23
EP3707149A1 (en) 2020-09-16
CN111527097A (en) 2020-08-11
KR20200081443A (en) 2020-07-07
CA3080128A1 (en) 2019-05-09
AU2018361991A1 (en) 2020-05-14
WO2019089080A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
IL274162A (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
IL279752B (en) Polycyclic compounds and use thereof in the treatment of immune disorders
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
SI3227237T1 (en) Device and use thereof for the uv treatment of fluids
IL290150A (en) Compositions and methods for the treatment of chronic pain
IL290754A (en) Use of pridopidine for the treatment of anxiety and depression
IL257173A (en) Novel insulin derivatives and the medical uses hereof
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
GB201617064D0 (en) Compounds and their therapeutic use
GB201715194D0 (en) Compounds and their therapeutic use
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
HK1257584A1 (en) Medicine for preventing and treating systemic sclerosis and use of the medicine
IL272097A (en) Compounds for the prevention and treatment of medical disorders and uses thereof
IL271878A (en) Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions
SI3452465T1 (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
EP3723742C0 (en) Use of fluoroethylnormemantine for the prevention and treatment of anxiety
EP3697387A4 (en) Combination of as1411 and sapc-dops for the treatment of glioblastoma multiforme
IL275349A (en) Use of hm4di in the treatment of seizure disorders
IL274838A (en) Use of mir101 or mir128 in the treatment of seizure disorders
IL273863A (en) Device for use in the treatment of hemorrhoids
HK1257593A1 (en) New drug for treating diabetes and use thereof
GB201819430D0 (en) Therapeutic compounds, nanoparticles and uses thereof
EP3604310A4 (en) Cdc-7-inhibitor compounds and use thereof for the treatment of neurological conditions
GB201915641D0 (en) Glucose-responsive insulin analogs and methods of use thereof
RS63107B1 (en) Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation